Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075237 | 0.82 | POLB (0.69) | POLBMEN1KMT2APDK2NPC1 | |
| SCHEMBL13096997 | 0.82 | POLB (0.73) | POLBMEN1KMT2APDK2NPC1 | |
| SCHEMBL2227579 | 0.82 | POLB (0.69) | POLBMEN1KMT2APDK2NPC1 | |
| SCHEMBL5779184 | 0.81 | MAOA (0.49) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL23640346 | 0.81 | POLB (0.71) | POLBMEN1KMT2APDK2NPC1 | |
| SCHEMBL13106477 | 0.81 | POLB (0.67) | POLBMEN1KMT2APDK2NPC1 | |
| SCHEMBL1283353 | 0.80 | LTA4H (0.61) | POLB | |
| SCHEMBL29417804 | 0.80 | LTA4H (0.61) | POLB | |
| SCHEMBL13185148 | 0.80 | POLB (0.66) | POLBMEN1KMT2APDK2NPC1 | |
| SCHEMBL2553749 | 0.80 | PDK2 (0.49) | POLBMEN1KMT2APDK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| EP-1615890-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | POLB 4028/4885MEN1 1399/4885KMT2A 1197/4885 |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | POLB 1242/4885MEN1 4236/4885KMT2A 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.